Malignant Ovarian Serous Tumor

subtype

Identifier: CI-CAN-00003206
Entity page: /cancer/malignant-ovarian-serous-tumor ↗
Edges: 340

Neighbours: 17 genes2 variants17 drugs10 trials
Drawn: 46 of 46 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Ovarian Serous Tumor predicts response to …PREDICTS_RESPONSE_TO2 of 2
in context · predicts response to	KRAS Mutationother → predicts response to Binimetinib	sensitivity	B	Malignant Ovarian Serous Tumor	1	Curated	civic	graph →
in context · predicts response to

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

KRAS Mutation Binimetinib1 active / 1 trials
Curatedlevel Bsensitivity· support 1civicObservedKRAS altered in 32% (38 / 119 cases)no approval record in this cancercontext: Malignant Ovarian Serous Tumor
BRAF V600E Vemurafenib0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for BRAF in this cancerno approval record in this cancercontext: Ovarian Serous Adenocarcinoma
CUL1 Fusion Mitogen-Activated Protein Kinase Kinase Inhibitor0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for CUL1 in this cancerno approval record in this cancercontext: Ovarian Serous Adenocarcinoma
MAP2K1 Q56_V60del Selumetinib0 active / 1 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for MAP2K1 in this cancerno approval record in this cancercontext: Ovarian Serous Adenocarcinoma
NRAS Q61K TrametinibFDA US 2013-05-29 · tumour-agnostic0 active / 1 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for NRAS in this cancerRegulatoryapproved (2 approval records)context: Malignant Ovarian Serous Tumor
CDK12 Loss-of-function Olaparib10 active / 15 trials
Curatedlevel Dsensitivity· support 1civicObservedCDK12 altered in 4.9% (20 / 405 cases)no approval record in this cancercontext: Ovarian Serous Adenocarcinoma
CCNE1 Amplification Akt Inhibitor MK22060 active / 0 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for CCNE1 in this cancerno approval record in this cancercontext: Ovarian Serous Cystadenocarcinoma
CCNE1 Amplification Dinaciclib0 active / 0 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for CCNE1 in this cancerno approval record in this cancercontext: Ovarian Serous Cystadenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Malignant Ovarian Serous Tumor associated with …ASSOCIATED_WITH2 of 2
← associated with	KRAS	supports	B	Malignant Ovarian Serous Tumor	1	Curated	civic	graph →
← associated with	NRAS	supports	C	Malignant Ovarian Serous Tumor	1	Curated	civic	graph →

Malignant Ovarian Serous Tumor investigated for …INVESTIGATED_FOR2 of 2
← investigated for	Binimetinibsmall_molecule	supports	B	Malignant Ovarian Serous Tumor	1	Curated	civic	graph →
← investigated for	Trametinibsmall_molecule	supports	C	Malignant Ovarian Serous Tumor	1	Curated	civic	graph →

Malignant Ovarian Serous Tumor altered in cohorts of …ALTERED_INderived15 of 117show all (up to 200)
← altered in cohorts of	TP53 483 / 603 cases (80 %) · ssm · TCGA-OV · largest of 6 cohorts	—	—	Ovarian Serous Cystadenocarcinoma	6	Observed	gdc	graph →
← altered in cohorts of	MYC 455 / 603 cases (75 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FAM135B 449 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	POU5F1B 449 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTRT3 447 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ADCY8 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AGO2 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRC34 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MYNN 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PTK2 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	GPR20 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	GSDMC 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRATD2 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRC31 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRIQ4 445 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →

Malignant Ovarian Serous Tumor investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 63show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 35 trials (12 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 28 trials (11 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 26 trials (14 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 15 trials (10 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 11 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 8 trials (2 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 7 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 7 trials (6 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Letrozolesmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Cediranibsmall molecule 4 trials (4 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Veliparibsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Malignant Ovarian Serous Tumor	4	Observed	clinicaltrials	graph →

Malignant Ovarian Serous Tumor studied in …STUDIED_INderived10 of 154show all (up to 200)
→ studied in	NCT05956093NA · active not recruiting 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study · condition mapped ONTOLOGY_EXACT · 154 trials mapped (77 active)	—	—	High-Grade Serous Ovarian Cancer	1	Observed	clinicaltrials	graph →
→ studied in	NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 154 trials mapped (77 active)	—	—	Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03564340Phase 1/Phase 2 · recruiting Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers · condition mapped ONTOLOGY_EXACT · 154 trials mapped (77 active)	—	—	Low-Grade Serous Ovarian Cancer	1	Observed	clinicaltrials	graph →
→ studied in	NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 154 trials mapped (77 active)	—	—	Ovarian High Grade Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 154 trials mapped (77 active)	—	—	Ovarian High Grade Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07832227Phase 2 · not yet recruiting Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial · condition mapped ALIAS · 154 trials mapped (77 active)	—	—	Ovarian Low Grade Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07821879recruiting Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 154 trials mapped (77 active)	—	—	High-Grade Serous Ovarian Cancer	1	Observed	clinicaltrials	graph →
→ studied in	NCT04575935Phase 3 · recruiting Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial · condition mapped ONTOLOGY_EXACT · 154 trials mapped (77 active)	—	—	Ovarian Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07772869NA · recruiting Uterine Lavage to Detect Ovarian Cancer Risk · condition mapped ONTOLOGY_EXACT · 154 trials mapped (77 active)	—	—	Ovarian High Grade Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04633239Phase 1 · recruiting Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 154 trials mapped (77 active)	—	—	Ovarian High Grade Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →